Academic Radiology
Volume 17, Issue 2 , Pages 157-162 , February 2010

Effect of Improving the Quality of Radiographic Interpretation on the Ability to Predict Pulmonary Tuberculosis Relapse

  • Jason E. Stout, MD, MHS

      Affiliations

    • Division of Infectious Diseases & International Health, Department of Medicine, 3306-Duke University Medical Center, Durham, NC 27710
    • Corresponding Author InformationAddress correspondence to: J.E.S.
    • ,
  • Andrzej S. Kosinski, PhD

      Affiliations

    • Department of Biostatistics and Bioinformatics, 3306-Duke University Medical Center, Durham, NC 27710
    • ,
  • Carol Dukes Hamilton, MD, MHS

      Affiliations

    • Division of Infectious Diseases & International Health, Department of Medicine, 3306-Duke University Medical Center, Durham, NC 27710
    • ,
  • Philip C. Goodman, MD

      Affiliations

    • Division of Thoracic Imaging, Department of Radiology, 3306-Duke University Medical Center, Durham, NC 27710
    • ,
  • Ann Mosher, MPH, FNP

      Affiliations

    • Division of Infectious Diseases & International Health, Department of Medicine, 3306-Duke University Medical Center, Durham, NC 27710
    • ,
  • Dick Menzies, MD

      Affiliations

    • Montreal Chest Institute, McGill University, Montreal, Quebec, Canada
    • ,
  • Neil Schluger, MD

      Affiliations

    • Division of Pulmonary Allergy & Critical Care Medicine, Columbia University College of Physicians & Surgeons, New York, NY
    • ,
  • Awal Khan, PhD

      Affiliations

    • Centers for Disease Control and Prevention, Atlanta, GA
    • ,
  • John L. Johnson, MD

      Affiliations

    • Division of Infectious Diseases, Case Western Reserve University, Cleveland, OH
    • ,
  • Tuberculosis Trials Consortium

Received 31 July 2009 ,Accepted 10 August 2009.

References 

  1. Blumberg HM, Burman WJ, Chaisson RE, et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med. 2003;167:603–662
  2. Benator D, Bhattacharya M, Bozeman L, et al. Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial. Lancet. 2002;360:528–534
  3. Nyboe J. Results of the international study on x-ray classification. Bull Int Union Tuberc. 1968;41:115–124
  4. Zellweger JP, Heinzer R, Touray M, et al. Intra-observer and overall agreement in the radiological assessment of tuberculosis. Int J Tuberc Lung Dis. 2006;10:1123–1126
  5. Kwong JS, Carignan S, Kang EY, et al. Miliary tuberculosis. Diagnostic accuracy of chest radiography. Chest. 1996;110:339–342
  6. Graham S, Das GK, Hidvegi RJ, et al. Chest radiograph abnormalities associated with tuberculosis: reproducibility and yield of active cases. Int J Tuberc Lung Dis. 2002;6:137–142
  7. Yerushalmy J, Garland LH, Harkness JT, et al. An evaluation of the role of serial chest roentgenograms in estimating the progress of disease in patients with pulmonary tuberculosis. Am Rev Tuberc. 1951;64:225–248
  8. Balabanova Y, Coker R, Fedorin I, et al. Variability in interpretation of chest radiographs among Russian clinicians and implications for screening programmes: observational study. BMJ. 2005;331:379–382
  9. Dawson-Saunders B, Trapp R. Estimating and comparing proportions. Basic and clinical biostatistics. Englewood Cliffs, NJ: Appleton and Lange; 1994;
  10. Benjamin DK, DeLong E, Steinbach WJ. Latent class analysis: an illustrative application for education in the assessment of resident otoscopic skills. Ambul Pediatr. 2004;4:13–17
  11. Walter SD, Irwig LM. Estimation of test error rates, disease prevalence and relative risk from misclassified data: a review. J Clin Epidemiol. 1988;41:923–937
  12. Kosinski AS, Barnhart HX. Accounting for nonignorable verification bias in assessment of diagnostic tests. Biometrics. 2003;59:163–171
  13. Little RJA, Rubin DB. Statistical analysis with missing data. New York: Wiley; 1987;
  14. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33:159–174
  15. Schmidt PG. [Open negative cavities.]. Tuberkulosearzt. 1963;17:137–151
  16. Oyama T, Tatsuoka M. Prediction of relapse in pulmonary tuberculosis; an application of discriminant analysis. Am Rev Tuberc. 1956;73:472–484
  17. Tripathy SP. Relapse in tuberculosis. Ind J Tuberc. 1981;28:45–57
  18. Aber VR, Nunn AJ. [Short term chemotherapy of tuberculosis. Factors affecting relapse following short term chemotherapy]. Bull Int Union Tuberc. 1978;53:260–264
  19. Johnson JL, Okwera A, Vjecha MJ, et al. Risk factors for relapse in human immunodeficiency virus type 1 infected adults with pulmonary tuberculosis. Int J Tuberc Lung Dis. 1997;1:446–453
  20. Waaler HT. Description of the study material and organization of the study. Bull Int Union Tuberc. 1968;41:110–114
  21. Den Boon S, Bateman ED, Enarson DA, et al. Development and evaluation of a new chest radiograph reading and recording system for epidemiological surveys of tuberculosis and lung disease. Int J Tuberc Lung Dis. 2005;9:1088–1096
  22. Albaum MN, Hill LC, Murphy M, et al. Interobserver reliability of the chest radiograph in community-acquired pneumonia. PORT Investigators. Chest. 1996;110:343–350
  23. Spearman C. The proof and measurement of association between two things. Am J Psychol. 1904;15:72–101
  24. Thomas D, Stram D, Dwyer J. Exposure measurement error: influence on exposure-disease. Relationships and methods of correction. Annu Rev Public Health. 1993;14:69–93
  25. Koppaka R, Bock N World Health Organization. How reliable is chest radiography?. In:  Toman K,  Frieden T editor. Toman's tuberculosis case detection, treatment, and monitoring: questions and answers. Geneva: World Health Organization; 2004;p. 51–60

 USPHS/TB Trials Consortium Study 22 was sponsored by the United States Centers for Disease Control and Prevention and was funded in part through a Memorandum of Understanding between the CDC and the Washington, D.C. Veterans Affairs Medical Center. Hoechst Marion Roussel, the manufacturer of rifapentine, provided rifapentine and contributed to the cost of 3 investigator meetings, but did not participate in original or secondary analysis study design, data collection, data analysis, data interpretation, or writing of the report. Dr. Stout received salary support from the National Institutes of Health (K23AI051409). Dr. Hamilton also received salary support from the National Institutes of Health (K24AI001833).

PII: S1076-6332(09)00503-0

doi: 10.1016/j.acra.2009.08.013

Academic Radiology
Volume 17, Issue 2 , Pages 157-162 , February 2010

Article Tools

* Image Usage & Resolution